This is potentially good news, say the researchers, who published their study in the Nov. 17 issue of the Journal of Cell Biology. If this protein — known as p120 catenin — is that powerful, it may be possible to turn the tables on cancer by designing an agent that would suppress it.
"We believe p120 could be an excellent target for therapy," says the study's lead investigator, Panos Anastasiadis, Ph.D., a Mayo Clinic cancer researcher. "Most cancer therapies target cancer growth, but miss migrating cancer cells that eventually re-establish the tumor, often at distant sites. Our best hope for long-term cancer therapy is to target both cancer cell growth and tumor spread, or metastasis.
"An anti-p120 agent could provide a much-needed double whammy — stop cancer spread and shut down growth at the same time."
Dr. Anastasiadis adds that while the discovery was made in breast cancer cells, it has relevance to a number of cancers, including those of the lung, kidneys, and skin, in which p120 plays a role. "These findings have significant implications for our understanding of tumor biology and for improving cancer treatment," he says.
This study expands upon a body of research at the Mayo Clinic campus that is uniquely devoted to understanding, and then halting, cancer metastasis. Dr. Anastasiadis and his collaborators, including study co-author Edith Perez, M.D., a Mayo Clinic oncologist in the Breast Cancer Program, had earlier discovered that p120 activity is necessary if cancer is to spread. But they did not know about its role in growth promotion until this latest work.
P120 acts in cells by regulating the function of proteins called cadherins. Cadherins are membrane proteins that help cells stick to each other to form a tissue. On the outside of a cell's membrane, they act like Velcro, fusing to other cadherin proteins on adjacent cells. On the inside, they latch on to a chainwork of catenins, which are proteins that regulate a cell's shape and function. The best understood of the cadherins is E-cadherin, which binds all epithelial cells to each other, forming layers that cover the inside of organs and body cavities, and the outside skin of humans. In short, E-cadherin holds a human's cells and tissues together, Dr. Anastasiadis says.
P120 normally binds onto E-cadherin, strengthening cell-cell bonding. But in some cases it detaches from E-cadherin, which allows the cell to lose its adhesive grip to adjacent cells and switch on a program that promotes cell movement. The loss of E-cadherin expression during a process known as epithelial-mesenchymal transition (EMT) is one mechanism of activating p120's pro-migratory function, the researchers say. EMT is necessary during human development, or during wound healing in adults. But it is a process that is hijacked by tumors to allow cancer cells to migrate and colonize other organs. "When E-cadherin production is lost during the progression of cancer, p120 catenin induces invasion and metastasis," Dr. Anastasiadis says.
In this study, the researchers discovered that not only does p120 promote metastasis when it is not bound to E-cadherin, it also turns on growth-promoting genes and proteins. In laboratory and animal experiments, they found that "free" p120 makes cancer very aggressive, able to grow in conditions that other cancer cells can't. They specifically found that p120 activates a family of molecules that includes Ras and Rho, which promote cell growth and movement.
"What is really interesting here is that p120 is acting like a tumor suppressor when it is bound to E-cadherin, and like a tumor promoter when it isn't," Dr. Anastasiadis says.
The researchers believe these findings could help explain why in some solid tumors, such as breast, lung, kidney, and melanoma, loss of E-cadherin is associated with a more aggressive, less treatable prognosis. "We think that when E-cadherin is lost, p120 is now free to turn on growth promotion pathways that can overtake the benefits of targeted chemotherapeutics," he says.
"So in breast cancer that is HER2-positive, anti-HER2 therapies such as Herceptin will not function well if p120 has turned on alternate growth mechanisms," Dr. Anastasiadis says. "A similar effect would also be expected in EGFR-positive lung cancer and anti-EGFR treatment." Both HER2 and EGFR are growth-promotion proteins.
A potential solution would be to design an agent that targets the tumor-promoting function of p120 that is not bound to E-cadherin, he says. "This won't be easy, but based on our current understanding of p120 function we believe it is possible," says Dr. Anastasiadis.
Other co-authors include Edwin Soto, Masahiro Yanagisawa M.D., Ph.D., Laura Marlow, and John Copland, Ph.D. The study was funded by the National Institutes of Health and the Breast Cancer Research Foundation.
Paul Scotti | EurekAlert!
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences